Device for Delivery of Rheumatoid Arthritis Medication
US-2017157380-A1 · Jun 8, 2017 · US
US12042284B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12042284-B2 |
| Application number | US-201815878313-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 23, 2018 |
| Priority date | Jan 23, 2018 |
| Publication date | Jul 23, 2024 |
| Grant date | Jul 23, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Embodiments of the invention provide optimized polymeric surfaces adapted for use with implantable medical devices as well as methods for making and using such polymeric surfaces. These polymer surfaces have a constellation of features that function to inhibit or avoid an inflammatory immune response generated by implantable medical devices. Typical embodiments of the invention include an implantable glucose sensor used in the management of diabetes having a polymer surface with the disclosed constellation of features.
Opening claim text (preview).
The invention claimed is: 1. A method of avoiding an inflammatory response to an implanted medical device comprising implanting the implantable medical device having a surface adapted to contact an in vivo environment, the surface comprising a polyimide composition having the following characteristics: a carbon-to-oxygen ratio greater than 5 to 1; a surface hydrophobicity of between 75° and 90°; a surface topography characterized by at least one of (a)-(c): (a) grooves having an average peak-to-valley height of between 0.3 μm and 5 μm; (b) wells having an average peak-to-valley height of between 1 μm and 2 μm; and (c) grids having an average peak-to-valley height of between 2 μm and 4 μm; wherein: the surface avoids the inflammatory response by having surface characteristics such that when exposed to the surface comprising the polymer composition, RAW264.7 macrophages are influenced to differentiate into an anti-inflammatory (M2) phenotype. 2. The method of claim 1 , wherein the implantable medical device is implanted in an interstitial space. 3. The method of claim 1 , wherein the implantable medical device is a glucose sensor. 4. A polymer composition that forms a surface comprising: a carbon-to-oxygen ratio greater than 5 to 1; a surface hydrophobicity of between 75° and 90°; a surface topography characterized by at least one of (a)-(c): (a) grooves having an average peak-to-valley height of between 0.3 μm and 5 μm; (b) wells having an average peak-to-valley height of between 1 μm and 2 μm; and (c) grids having an average peak-to-valley height of between 2 μm and 4 μm; wherein: when exposed to the surface, RAW264.7 macrophages are influenced to differentiate into an anti-inflammatory (M2) phenotype.
Antifouling coatings characterised by surface structure, e.g. for roughness effect giving superhydrophobic coatings or Lotus effect · CPC title
Detecting, measuring or recording for evaluating the immune or lymphatic systems · CPC title
for interstitial fluid · CPC title
for glucose · CPC title
for measuring glucose, e.g. by tissue impedance measurement · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.